38 C.F.R. § 3.317
(a) Compensation for disability due to undiagnosed illness and medically unexplained chronic multisymptom illnesses.
(1) Except as provided in paragraph (a)(7) of this section, VA will pay compensation in accordance with chapter 11 of title 38, United States Code, to a Persian Gulf veteran who exhibits objective indications of a qualifying chronic disability, provided that such disability:
(2)
(i) For purposes of this section, a qualifying chronic disability means a chronic disability resulting from any of the following (or any combination of the following):
(B) A medically unexplained chronic multisymptom illness that is defined by a cluster of signs or symptoms, such as:
(1) Chronic fatigue syndrome;
(2) Fibromyalgia;
(3) Functional gastrointestinal disorders (excluding structural gastrointestinal diseases).
(7) Compensation shall not be paid under this section for a chronic disability:
(b) Signs or symptoms of undiagnosed illness and medically unexplained chronic multisymptom illnesses. For the purposes of paragraph (a)(1) of this section, signs or symptoms which may be manifestations of undiagnosed illness or medically unexplained chronic multisymptom illness include, but are not limited to:
(c) Presumptive service connection for infectious diseases.
(2) The diseases referred to in paragraph (c)(1) of this section are the following:
(3) The diseases listed in paragraph (c)(2) of this section will be considered to have been incurred in or aggravated by service under the circumstances outlined in paragraphs (c)(3)(i) and (ii) of this section even though there is no evidence of such disease during the period of service.
(4) A disease listed in paragraph (c)(2) of this section shall not be presumed service connected:
(d) Long-term health effects potentially associated with infectious diseases.
(2) If a veteran presumed service connected for one of the diseases listed in paragraph (c)(2) of this section is diagnosed with one of the diseases listed in column “B” in the table within the time period specified for the disease in the same table, if a time period is specified or, otherwise, at any time, VA will request a medical opinion as to whether it is at least as likely as not that the condition was caused by the veteran having had the associated disease in column “A” in that same table.
| A | B |
|---|---|
| Disease | |
| Brucellosis | • Arthritis. |
| • Cardiovascular, nervous, and respiratory system infections. | |
| • Chronic meningitis and meningoencephalitis. | |
| • Deafness. | |
| • Demyelinating meningovascular syndromes. | |
| • Episcleritis. | |
| • Fatigue, inattention, amnesia, and depression. | |
| • Guillain-Barré syndrome. | |
| • Hepatic abnormalities, including granulomatous hepatitis. | |
| • Multifocal choroiditis. | |
| • Myelitis-radiculoneuritis. | |
| • Nummular keratitis. | |
| • Papilledema. | |
| • Optic neuritis. | |
| • Orchioepididymitis and infections of the genitourinary system. | |
| • Sensorineural hearing loss. | |
| • Spondylitis. | |
| • Uveitis. | |
| Campylobacter jejuni | • Guillain-Barré syndrome if manifest within 2 months of the infection. |
| • Reactive Arthritis if manifest within 3 months of the infection. | |
| • Uveitis if manifest within 1 month of the infection. | |
| Coxiella burnetii (Q fever) | • Chronic hepatitis. |
| • Endocarditis. | |
| • Osteomyelitis. | |
| • Post-Q-fever chronic fatigue syndrome. | |
| • Vascular infection. | |
| Malaria | • Demyelinating polyneuropathy. |
| • Guillain-Barré syndrome. | |
| • Hematologic manifestations (particularly anemia after falciparum malaria and splenic rupture after vivax malaria). | |
| • Immune-complex glomerulonephritis. | |
| • Neurologic disease, neuropsychiatric disease, or both. | |
| • Ophthalmologic manifestations, particularly retinal hemorrhage and scarring. | |
| • Plasmodium falciparum. | |
| • Plasmodium malariae. | |
| • Plasmodium ovale. | |
| • Plasmodium vivax. | |
| • Renal disease, especially nephrotic syndrome. | |
| Mycobacterium tuberculosis | • Active tuberculosis. |
| • Long-term adverse health outcomes due to irreversible tissue damage from severe forms of pulmonary and extrapulmonary tuberculosis and active tuberculosis. | |
| Nontyphoid Salmonella | • Reactive Arthritis if manifest within 3 months of the infection. |
| Shigella | • Hemolytic-uremic syndrome if manifest within 1 month of the infection. |
| • Reactive Arthritis if manifest within 3 months of the infection. | |
| Visceral leishmaniasis | • Delayed presentation of the acute clinical syndrome. |
| • Post-kala-azar dermal leishmaniasis if manifest within 2 years of the infection. | |
| • Reactivation of visceral leishmaniasis in the context of future immunosuppression. | |
| West Nile virus | • Variable physical, functional, or cognitive disability. |
(e) Service. For purposes of this section:
(2) The Southwest Asia theater of operations refers to Iraq, Kuwait, Saudi Arabia, the neutral zone between Iraq and Saudi Arabia, Bahrain, Qatar, the United Arab Emirates, Oman, the Gulf of Aden, the Gulf of Oman, the Persian Gulf, the Arabian Sea, the Red Sea, and the airspace above these locations.
(Authority: 38 U.S.C. 1117, 1118)
Note to paragraph (a)(2)(i)(B)(3): Functional gastrointestinal disorders are a group of conditions characterized by chronic or recurrent symptoms that are unexplained by any structural, endoscopic, laboratory, or other objective signs of injury or disease and may be related to any part of the gastrointestinal tract. Specific functional gastrointestinal disorders include, but are not limited to, irritable bowel syndrome, functional dyspepsia, functional vomiting, functional constipation, functional bloating, functional abdominal pain syndrome, and functional dysphagia. These disorders are commonly characterized by symptoms including abdominal pain, substernal burning or pain, nausea, vomiting, altered bowel habits (including diarrhea, constipation), indigestion, bloating, postprandial fullness, and painful or difficult swallowing. Diagnosis of specific functional gastrointestinal disorders is made in accordance with established medical principles, which generally require symptom onset at least 6 months prior to diagnosis and the presence of symptoms sufficient to diagnose the specific disorder at least 3 months prior to diagnosis.
[75 FR 59970, Sept. 29, 2010, as amended at 75 FR 61356, Oct. 5, 2010; 75 FR 61997, Oct. 7, 2010; 76 FR 41698, July 15, 2011; 76 FR 81836, Dec. 29, 2011; 81 FR 71384, Oct. 17, 2016; 86 FR 51001, Sept. 14, 2021]